Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001
· Last participant has been randomised in clinical trial 0205 investigating efficacy and safety of CT001 relative to placebo and two comparative active arms · Primary aim is to show that CT001 offers a better pain reduction and safety profile compared to the comparative arms and placebo · Top-line results are anticipated during Q4 2023 once data has been analysedCopenhagen, Denmark, 21 September - Cessatech A/S (“Cessatech” or “the Company”) announces that the last participant has been randomized in clinical trial 0205, investigating the postoperative analgesic efficacy of CT001 in